TLR7/8 agonist 13

• Target:

  Interleukin|||TLR|||HBV|||IFNAR

• Related Pathways:

  Microbiology/Virology|||Immunology/Inflammation

• Bioactivity:

  TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (with a lowest effective concentration (LEC) [hTLR7] of 1.6 ?M) and TLR8 (LEC [hTLR8] of 1.6 ?M) . It acts on human peripheral blood mononuclear cells (hPBMC) with agonistic activity (LEC [hPBMC] = 0.5 ?M) . In mice and cynomolgus monkeys, TLR7/8 agonist 13 induces endogenous IFN?, activates myeloid dendritic cells and monocytes, promoting their differentiation towards a TH1 phenotype. In chronic AAV-HBV mouse models, it reduces viral load and HBV surface antigen levels. TLR7/8 agonist 13 has the potential to indirectly induce IFN?, facilitating the response of HBV antigen-specific CD8 T cells. This compound is useful for hepatitis B virus research.

• Smiles:

  N([C@@H](CCCC)CCO)C=1C(OC)=CN=C(N)N1

• Molecular Formula:

  C12H22N4O2

• Molecular Weight:

  254.33

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  1402802-45-2